2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance
Journal Volume
118
Journal Issue
10
Pages
1385-1392
Date Issued
2019
Author(s)
Abstract
Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy. ? 2018 Formosan Medical Association
SDGs
Other Subjects
atorvastatin; fluindostatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; lipid; mevinolin; pitavastatin; pravastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; atherosclerosis; chronic liver disease; disease course; drug hypersensitivity; health care personnel; human; liver disease; liver function; muscle disease; patient care; practice guideline; Review; risk factor; Taiwan; treatment planning; blood; chronic disease; complication; consensus; liver disease; muscle disease; toxic hepatitis; Chemical and Drug Induced Liver Injury; Chronic Disease; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Muscular Diseases; Risk Factors; Taiwan
Type
review